{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T17:08:29Z","timestamp":1726420109806},"reference-count":25,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2006,12,1]],"date-time":"2006-12-01T00:00:00Z","timestamp":1164931200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2006,12]]},"DOI":"10.1016\/j.ijantimicag.2006.07.010","type":"journal-article","created":{"date-parts":[[2006,10,15]],"date-time":"2006-10-15T07:23:09Z","timestamp":1160896989000},"page":"532-536","source":"Crossref","is-referenced-by-count":9,"title":["Activity of tigecycline against clinical isolates of Staphylococcus aureus and extended-spectrum \u03b2-lactamase-producing Escherichia coli in Granada, Spain"],"prefix":"10.1016","volume":"28","author":[{"given":"A.","family":"Sorl\u00f3zano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Salmer\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.D.","family":"Luna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Mart\u00ednez-Checa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Rom\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Pi\u00e9drola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2006.07.010_bib1","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1128\/AAC.43.4.738","article-title":"In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936)","volume":"43","author":"Petersen","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2006.07.010_bib2","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1086\/431670","article-title":"Overview of antibiotic use and resistance: setting the stage for tigecycline","volume":"41","author":"Zinner","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2006.07.010_bib3","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1086\/431672","article-title":"Tigecycline: a new glycylcycline for treatment of serious infections","volume":"41","author":"Noskin","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2006.07.010_bib4","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0732-8893(99)00092-9","article-title":"Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates","volume":"36","author":"Gales","year":"2000","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2006.07.010_bib5","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1592\/phco.20.14.219S.35046","article-title":"Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent","volume":"20","author":"Projan","year":"2000","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2006.07.010_bib6","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1128\/AAC.48.6.2179-2184.2004","article-title":"Effects of efflux transporter genes on susceptibility of Escherichia coli to tigecycline (GAR-936)","volume":"48","author":"Hirata","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2006.07.010_bib7","doi-asserted-by":"crossref","first-page":"4240","DOI":"10.1128\/AAC.48.11.4240-4245.2004","article-title":"Evolution of the antimicrobial resistance of Staphylococcus spp. in Spain: five nationwide prevalence studies, 1986 to 2002","volume":"48","author":"Cuevas","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2006.07.010_bib8","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/j.1469-0691.2004.00830.x","article-title":"Methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to glycopeptides (GISA) in 63 French general hospitals","volume":"10","author":"Cartolano","year":"2004","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2006.07.010_bib9","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1128\/CMR.14.4.933-951.2001","article-title":"Extended-spectrum \u03b2-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat","volume":"14","author":"Bradford","year":"2001","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2006.07.010_bib10","unstructured":"Sorl\u00f3zano A, Guti\u00e9rrez J, Luna J,D, et al. High presence of extended-spectrum \u03b2-lactamases and resistance to quinolones in clinical isolates of Escherichia coli. Microbiol Res 2006 Mar 23 [Epub ahead of print]."},{"key":"10.1016\/j.ijantimicag.2006.07.010_bib11","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0732-8893(02)00358-9","article-title":"Potency and antimicrobial spectrum update for piperacillin\/tazobactam (2000): emphasis on its activity against resistant organism populations and generally untested species causing community-acquired respiratory tract infections","volume":"43","author":"Johnson","year":"2002","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2006.07.010_bib12","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1128\/AAC.48.1.224-228.2004","article-title":"Risk factors for acquisition of imipenem-resistant Acinetobacter baumannii: a case\u2013control study","volume":"48","author":"Lee","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2006.07.010_bib13","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1128\/JCM.38.4.1339-1346.2000","article-title":"Evaluation of the Wider system, a new computer-assisted image-processing device for bacterial identification and susceptibility testing","volume":"38","author":"Canton","year":"2000","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2006.07.010_bib14","unstructured":"Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 15th informational supplement. M100-S15. Wayne, PA: CLSI; 2005."},{"key":"10.1016\/j.ijantimicag.2006.07.010_bib15","first-page":"227","article-title":"A preliminary study on the presence of extended-spectrum beta-lactamases (ESBL) in clinical isolates of Escherichia coli in Granada (Spain)","volume":"54","author":"Sorl\u00f3zano","year":"2004","journal-title":"Ann Microbiol"},{"key":"10.1016\/j.ijantimicag.2006.07.010_bib16","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1093\/jac\/dki291","article-title":"Tigecycline: what is it, and where should it be used?","volume":"56","author":"Livermore","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2006.07.010_bib17","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0732-8893(01)00269-3","article-title":"In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum \u03b2-lactamases","volume":"40","author":"Biedenbach","year":"2001","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2006.07.010_bib18","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1128\/AAC.46.3.892-895.2002","article-title":"In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain","volume":"46","author":"Betriu","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2006.07.010_bib19","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1128\/AAC.47.1.400-404.2003","article-title":"Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates","volume":"47","author":"Milatovic","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2006.07.010_bib20","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.diagmicrobio.2004.08.007","article-title":"In vitro activities of tigecycline against clinical isolates from Shanghai, China","volume":"50","author":"Zhang","year":"2004","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2006.07.010_bib21","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1093\/jac\/dkh232","article-title":"Antimicrobial susceptibility of the pathogens of bacteraemia in the UK and Ireland 2001\u20132002: the BSAC Bacteraemia Resistance Surveillance Programme","volume":"53","author":"Reynolds","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2006.07.010_bib22","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.diagmicrobio.2004.03.002","article-title":"In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and gram-positive cutaneous infections","volume":"49","author":"Fritsche","year":"2004","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2006.07.010_bib23","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.diagmicrobio.2005.05.003","article-title":"Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000\u20132004)","volume":"52","author":"Fritsche","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2006.07.010_bib24","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.diagmicrobio.2005.05.002","article-title":"Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit","volume":"52","author":"Sader","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2006.07.010_bib25","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.diagmicrobio.2005.06.010","article-title":"Activity of tigecycline tested against a global collection of Enterobacteriaceae, including tetracycline-resistant isolates","volume":"52","author":"Fritsche","year":"2005","journal-title":"Diagn Microbiol Infect Dis"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857906003311?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857906003311?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,18]],"date-time":"2020-04-18T12:50:41Z","timestamp":1587214241000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857906003311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,12]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006,12]]}},"alternative-id":["S0924857906003311"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2006.07.010","relation":{},"ISSN":["0924-8579"],"issn-type":[{"type":"print","value":"0924-8579"}],"subject":[],"published":{"date-parts":[[2006,12]]}}}